January 8, 2021Open Access

Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

Key Points

Key points are not available for this paper at this time.

Abstract

Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Josep M. Piulats

Enrique Espinosa

Luis de la Cruz‐Merino

Journals

Journal of Clinical Oncology

Actions

Institutions

Universidad de Sevilla

Institut Català d'Oncologia

Institut d'Investigació Biomédica de Bellvitge

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study